Page 8 - Pharmaceutical Firms

Indore-based Modern Lab to manufacture Black Fungus drug Amphotericin B

The Madhya Pradesh government has given permission to the Indore-based Modern Laboratories to manufacture Amphotericin B drug used in the treatment of Black Fungus, White Fungus, and Yellow Fungus

Divi's Labs Q4 net profit jumps 29% at Rs 502 crore on robust sales

Drug firm Divi's Laboratories on Saturday reported a 29.30 percent rise in its consolidated net profit to Rs 502.02 crore for the quarter ended March 31, 2021, on account of robust sales

Zydus introduces scratch code in critical drug packs to fight counterfeit

Drug firm Zydus Cadila on Friday said it has introduced a new feature in the packaging of its critical drugs to help patients ensure that the product is not fake or counterfeited

Drugmaker Zydus Cadila's fourth quarter net profit up 73% at Rs 679 crore

Total income from operations of Rs 3,847 crore was up by 3 per cent from Rs 3,752 crore in Q4 FY20.

Pharma sector's Q4 results show moderate gains amid Covid-19 pandemic

The ongoing April-June quarter should see strong growth due to low base of last year

Covid second wave pushes India's pharma industry growth to 59% in April

The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector

Biotechnology major Biocon Q4 net profit surges 86% to Rs 296.4 crore

Biocon has reported 86.29% jump in consolidated profit to Rs 296.4 crore for the quarter ended March 31, 2021

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

Given the shortage of supplies, the Union government last week banned the export of Remdesivir

Clinically tried and tested: Bharat Biotech boss Ella wins Covaxin fight

Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January

PE firm Advent International acquires 51% stake in ZCL Chemicals

ZCL is one of the fastest-growing manufacturers of specialty active pharmaceutical ingredients (APIs) and advanced intermediates

Alembic Pharma gets five observations from USFDA for Gujarat facility

Alembic Pharmaceuticals on Monday said the US health regulator has made five observations after inspection at its facility at Karkhadi, Gujarat. "The United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' New Injectable Facility (F-3) located at Karkhadi from January 29-February 5, 2021. This was a scheduled inspection and at the end of the inspection, the USFDA issued a form 483 with 5 observations, the company said in a regulatory filing. As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. It notifies the company's management of objectionable conditions. Alembic Pharma said none of the observations were related to data integrity and were procedural in nature. "The company is preparing the response to the observations, which will be

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Despite heroic work for Covid vaccine, pharma cos don't deserve affection

A financial analyst recently told that Pfizer's involvement in the coronavirus pandemic was about "as much public relations as it is a financial return

Aurobindo, Zydus, Jubilant, others recall various products in US market

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

PLI scheme: Govt looks to get Rs 50,000 crore investments in pharma

The incentive will be in the range of 5-10 per cent of production value, sources said.

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

Zydus Cadila Q2 net up four-fold on surge in US sales, strong show at home

Firm prunes net debt by 40% since March 2020; consolidated income up 13%

With 350% stock gain, drugmaker Laurus Labs seeks to boost capacity

The pharmaceutical sector is the top performer in India's $2.1 trillion equity market this year after the coronavirus pandemic turned global investors' spotlight on health-care companies

Glenmark Pharma launches pulmonary fibrosis treatment drug in India

Glenmark Pharma announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India